Novartis Says 'No' on Alnylam IP Option as Alternate RNAi Approaches Gain Traction

The emergence of new RNAi chemistries and technologies in recent years, and big pharma's growing interest in building up its own capabilities, suggest that Alnylam's status as the go-to partner in the field may be waning.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.